Drug Profile
Scopolamine - GT Biopharma
Alternative Names: GTP-011; Repurposed scopolamine - GT BiopharmaLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Georgetown Translational Pharmaceuticals
- Developer GT Biopharma
- Class Antidepressants; Antiemetics; Antispasmodics; Hypnosedatives; Mydriatics; Small molecules; Tropanes
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Motion sickness
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for clinical-Phase-Unknown development in Motion-sickness in USA (Transdermal, Patch)
- 10 Apr 2018 GT Biopharma completes enrolment in its clinical trial for Motion sickness in USA
- 28 Feb 2018 Clinical trials in Motion sickness in USA (unspecified route)